Team von Bär & Karrer
Bär & Karrer agiert als Rechtsberaterin von Firmenich, zusammen mit der holländischen Kanzlei Stibbe. Das Team besteht aus Rolf Watter, Urs Kägi, Thomas Rohde, Rebecca Schori, Florian Schweighofer und Marie-Cristine Kaptan (alle M&A, Gesellschaftsrecht und Capital Markets).
Team von Walder Wyss
Walder Wyss beriet DSM bei dieser Transaktion. Das Team wurde geführt gemeinsam geführt durch Thomas Meister (Partner, Tax) und Thiemo Sturny (Partner, Capital Markets/M&A) und bestand weiter aus Dimitrios Berger (Senior Associate, Capital Markets/M&A), Janine Corti (Counsel, Tax), Alex Nikitine (Partner, Capital Markets/M&A), Lukas Wyss (Partner, Finance), Maurus Winzap (Partner, Tax), Fabienne Limacher (Partner, Tax), Ursina Gremminger (Managing Associate, Tax), Jan Ole Luuk (Counsel, Tax), Natascha Rizzi (Associate, Tax), Reto Jacobs (Partner, Competition), Gion Giger (Counsel, Competition), Alexander Gutmans (Notary), Jürg Fisch (Associate, Corporate/M&A ) and Milos Karic (Trainee, Corporate/M&A).
Information von Firmenich und DSM über die Transaktion
Die Unternehmen Firmenich und DSM informierten wie folgt über die Transaktion:
DSM and Firmenich to merge, becoming the leading creation and innovation partner in nutrition, beauty and well-being
- Merger of equals of two iconic companies – both with a track record of growth and a shared commitment to positively impact people and the planet – to create DSM-Firmenich
- Uniquely positioned to anticipate and address evolving consumer needs by supporting our customers
- Leveraging world-class science and complementary capabilities in fragrance, taste, texture and nutrition
- Accelerating strategic delivery by further boosting innovation in high-growth and resilient segments
- Attractive annual run rate synergy potential of €350m Adj. EBITDA, including c. €500m annual sales uplift particularly from combining DSM’s Food & Beverage and Firmenich’s Taste & Beyond businesses, supporting double-digit EPS accretion1
- Projected mid-term 5-7% sustainable organic sales growth per annum, driven by innovation and with mid-term adjusted EBITDA margin of 22-23%
- A Swiss-Dutch global group, with a Swiss domiciled holding company with the seat of the principal in Kaiseraugst (CH) and listed on Euronext Amsterdam
- DSM-Firmenich will have a dual headquarter in Switzerland (Kaiseraugst) and the Netherlands (Maastricht)
- DSM’s shareholders to own in aggregate 65.5% of DSM-Firmenich and the various Firmenich shareholders to own in aggregate 34.5% at inception
- Merger to be effected through public offer for DSM shares in exchange for DSM-Firmenich shares (1:1 exchange ratio) and contribution of Firmenich shares to DSM-Firmenich in exchange for DSM-Firmenich shares and €3.5bn cash (subject to potential adjustment)
- Merger subject to customary conditions, including obtaining relevant regulatory clearances and completing relevant employee consultation procedures, and expected to be completed ultimately in the first half of 2023
Thomas LeysenChairman of the DSM Supervisory Board: DSM-Firmenich will bring together leading creativity and cutting-edge science and innovation. Together we will be able to better serve the needs of customers and deliver compelling growth and returns. However, successful mergers require more than complementary capabilities or compelling financials; they not only require balanced governance and a respect of the interests of all stakeholders, but they crucially require shared values. My colleagues and I are convinced we have all of those elements, and it is for this reason that the Supervisory Board of DSM concluded that this is truly a merger which is in the interest of all stakeholders.
